scholarly journals Quality of Life of Patients with Stable Coronary Artery Disease Combined with Non-Alcoholic Fatty Liver Disease

2016 ◽  
Vol 23 (4) ◽  
pp. 2016416
Author(s):  
Iryna Vakalyuk ◽  
Nataliya Virstyuk ◽  
Vitaliy Petryna
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Stable Coronary Artery Disease ◽  
Control Group ◽  
Alcoholic Fatty Liver ◽  
Group I ◽  
Sf 36 ◽  
Artery Disease ◽  
Alcoholic Fatty Liver Disease

Quality of life assessment is an integral part of a comprehensive treatment in modern medical practice. Analysis of quality of life of patients with comorbidities is an interesting and poorly understood issue. The objective of the research was to evaluate the quality of life of patients with postinfarction cardiosclerosis depending on the presence and progression of non-alcoholic fatty liver disease (NAFLD).Material and methods. The research included 300 patients with stable coronary artery disease (CAD). They included 160 patients without NAFLD (Group I) and 140 patients with NAFLD (Group II). 89 patients of Group II suffered from non-alcoholic liver disease (NALD) and 51 patients from non-alcoholic steatohepatitis (NASH). The control group consisted of 20 apparently healthy individuals. SF-36 and MacNew questionnaires were used to assess the quality of life. Results. The overall estimate according to SF-36 questionnaire detected a significant decrease in the patient’s quality of life due to their low physical activity, mental ill-being, limitation of daily activities, significant effect of pain and low assessment of their health. Decrease in the quality of life was clearly dependent on NAFLD stage and was the lowest in case of NASH. The overall estimate of quality of life according to MacNew questionnaire was 1.5 times lower in patients of Group I compared to the control group, decreased almost by 1.4 times in patients with NALD compared to Group I and was 1.5 times lower in case of NASH compared to the patients with NALD (p<0.05). Conclusions. Patients with stable CAD combined with NAFLD were characterized by decrease in quality of life due to its physical, psycho-emotional and social components. Quality of life of patients with postinfarction cardiosclerosis depended on NAFLD progression and was the lowest in case of NASH.

Quality of life as an indicator of the effects of concomitant hypertensive disease on the state of health of patients with non-alcoholic fatty liver disease

2021 ◽  
Author(s):  
A. O. Rozhdestvenska
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Short Form ◽  
Control Group ◽  
Medical Outcomes ◽  
Alcoholic Fatty Liver ◽  
Sf 36 ◽  
The Mean ◽  
Chronic Liver Disease Questionnaire

Objective — to determine the effects of concomitant hypertension on the quality of life (QOL) of patients with non‑alcoholic fatty liver disease (NAFLD) using the Medical Outcomes Study Short Form (SF‑36) and The Chronic Liver Disease Questionnaire (CLDQ). Materials and methods. Examinations involved 115 patients with NAFLD at the stage of non‑alcoholic steatohepatitis. The patients were divided into two groups: the main group included 63 patients with NAFLD and hypertension (32 men and 31 women, the mean age 48.4 years) and comparison group consisted of 52 patients with NAFLD (25 men and 27 women, the mean age 48.3 years). The control group consisted of 20 practically healthy people (12 women and 8 men, the mean age 47.1 years). The NAFLD duration did not significantly differ between the groups of comorbid course (6.6 years (95 % confidence interval (CI) — 5.8; 7.3)) and isolated NAFLD (7.8 years (95 % CI 6.7; 8.8)) (p = 0.086). Hypertension duration was 8.4 years (95 % CI 7.3; 9.5). Assessments included body mass index calculation (BMI) and measurements of systolic (SBP) and diastolic (DBP) arterial pressure. The Medical Outcomes Study Short Form (SF‑36) and Chronic Liver Disease Questionnaire (CLDQ) were used to assess the QOL of NAFLD patients. Results. In comparison with the control group and regardless of the presence of concomitant pathology, the significant decrease in QOL scores of almost all SF‑36 scales was established in NAFLD patients. In NAFLD patients with hypertension, decrease in the QOL indicators was observed for all components of health, except for the results on the scale of physical functioning («PF»). Indicators of the total physical («PCS») and mental («MCS») health components were also significantly lower in the group with NAFLD and hypertension and amounted to 25.00 % (95 % CI 21.20; 29.60) and 44.00 % (95 % CI 42.23; 50.47) out of the maximum possible 100 %. There was a significant decrease in indicators for all domains of the CLDQ questionnaire in patients with NAFLD and hypertension compared to the isolated NAFLD and the control group. Significant inverse correlations were determined between the QOL indicators according to both questionnaires and the diseases duration, SBP, DBP levels and BMI. Conclusions. NAFLD is associated with significant deviant changes in patients’ quality of life indicators according to the SF‑36 and CLDQ questionnaires. The presence of concomitant hypertension, the duration of fatty changes in the liver, the experience of hypertension, the levels of SBP, DBP and BMI significantly worsen the QOL of patients with NAFLD. The quantitative variability of QOL components in patients with NAFLD and hypertension can negatively affect the course of the disease and reduce the effectiveness of therapeutic and rehabilitation measures.  

Mo1546 Health-Related Quality of Life and Health Utilities in Patients With Non-Alcoholic Fatty Liver Disease

2016 ◽  
Vol 150 (4) ◽  
pp. S1141
Author(s):  
Mehmet Sayiner ◽  
Maria Stepanova ◽  
Huong Pham ◽  
Bashir Noor ◽  
Mercedes Walters ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Health Related Quality ◽  
Alcoholic Fatty Liver ◽  
Related Quality ◽  
Health Related ◽  
Alcoholic Fatty Liver Disease

Quality of life of patients with non-alcoholic fatty liver disease with different thyroid status

2021 ◽  
pp. 57-61
Author(s):  
E. V. Chernyadeva ◽  
A. E. Shklyaev
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Primary Hypothyroidism ◽  
Alcoholic Fatty Liver ◽  
Personal Anxiety ◽  
Alcoholic Fatty Liver Disease ◽  
Ethylmethylhydroxypyridine Succinate

The aim. To study the quality of life and psychoemotional state of patients with non-alcoholic fatty liver disease against the background of primary hypothyroidism during the use of ethylmethylhydroxypyridine succinate.Materials and methods. 111 patients with non-alcoholic fatty liver were examined, among them 35 were without thyroid dysfunction, 55 with compensated primary hypothyroidism, 21 with decompensated hypothyroidism. The patients underwent general clinical, biochemical, enzyme-linked immunosorbent assays of blood, instrumental studies, testing according to psychological questionnaires.Results. With decompensation of hypothyroidism, a statistically significant increase in indicators of depression, situational and personal anxiety was revealed in comparison with patients without hypothyroidism. The examined patients showed an increase in the level of situational and personal anxiety. The presence of hypothyroidism in the examined patients significantly worsens these indicators, leading to an increase in the degree of anxiety, aggravated by decompensation of hypothyroidism. A positive dynamic was revealed in the correction of the psychoemotional status of patients in the observation group during the complex treatment with ethylmethylhydroxypyridine succinate: the severity of depression, situational and personal anxiety, manifestations of dyspeptic and reflux syndromes decreased.Conclusion. Hypothyroidism affects the quality of life and psycho-emotional state of patients with non-alcoholic fatty liver disease: it worsens the degree of depression, situational and personal anxiety. The addition of ethylmethylhydroxypyridine succinate to standard therapy with sodium levothyroxine in patients with non-alcoholic fatty liver disease in the setting of hypothyroidism improves the quality of life and psycho-emotional state.

scholarly journals Possible Amelioration of the Severity of Nutritional Steatohepatitis by Guggulsterone in Mice

2019 ◽  
Vol 28 (1) ◽  
pp. 17-23
Author(s):  
Sara Ameen Nafeer ◽  
Munaf Zalzala
Keyword(s):  
Liver Disease ◽  
High Fat Diet ◽  
Control Group ◽  
Free Access ◽  
High Fat ◽  
Alcoholic Fatty Liver ◽  
Commercial Diet ◽  
Group I ◽  
Alcoholic Fatty Liver Disease ◽  
Control Group Group

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide, which characterized by steatosis, inflammation, and fibrosis. The aim of this designed study is to evaluate the ability of guggulsterone to prevent high fat diet induced steatohepatitis in mice. Five groups of male mice were selected and treated as the following: group I, mice had free access to standard commercial diet and considered as control group, group II, mice were fed a specially formulated high-fat diet for 12 weeks to induce non-alcoholic liver disease, while groups III, IV and V the mice were administered high fat diet containing guggulsterone at 500, 1000 and 2000 ppm concentration respectively for 12 weeks. Maintaining mice on fat rich diet only resulted in inducing the metabolic and histological NAFLD associated. While the treatment with guggulsterone significantly improves the evaluated markers. These results demonstrate guggulsterone may be useful in preventing the development of steatohepatitis.

scholarly journals Paediatric Non-Alcoholic Fatty Liver Disease: Impact on Patients and Mothers’ Quality of Life

2013 ◽  
Vol 13 (3) ◽  
Author(s):  
Luigi Mazzone ◽  
Valentina Postorino ◽  
Lavinia De Peppo ◽  
Claudia Della Corte ◽  
Giuseppe Lofino ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Disease Impact ◽  
Alcoholic Fatty Liver Disease

scholarly journals Compressive Stockings After Hindfoot and Ankle Surgery

2018 ◽  
Vol 3 (3) ◽  
pp. 2473011418S0023
Author(s):  
Florian Grubhofer ◽  
Stephan Wirth
Keyword(s):  
Quality Of Life ◽  
Clinical Results ◽  
Control Group ◽  
End Points ◽  
High Compliance ◽  
Group I ◽  
Sf 36 ◽  
Ankle Surgery ◽  
Group Ii

Category: Hindfoot Introduction/Purpose: Swelling and pain are common after foot and ankle procedures. We hypothesized that compressive stockings (CS) treatment after hindfoot surgery would positively influence patient outcomes. Methods: We undertook this randomized controlled trial in 87 consecutive patients to analyze the clinical effect of CS after hindfoot and ankle surgery and evaluate CS-wearing compliance using sensors that were implanted into CS. Ankle swelling, pain status, quality of life (SF-36 score), and the American Orthopaedic Foot & Ankle Score (AOFAS) were set as the primary end points. The CS wearing time in hours and percentage were investigated as the secondary end points. All participants with CS (group I) were informed about the implanted sensor after the CS were taken off. A subgroup analysis of group I was performed to detect differences between patients with high vs low compliance. Results: At 12 weeks, the results of ankle swelling (mean 234 mm in group I and 232 mm in group II), pain in the visual analog scale (1.7 group I vs 1.9 in group II), the SF-36 score (38 points in group I vs 30 points in group II), and the AOFAS score (a mean of 76 points in both groups) showed no statistical differences between the 2 groups. The mean wearing time was 136 (range, 0-470) hours, which corresponds to a compliance rate of 65%. Sixteen participants had high compliance (>80%, >170 hours), and 21 patients had low or noncompliance. The clinical results of patients with high wearing compliance were not significantly better compared to the results of patients with low compliance. Conclusion: CS therapy after ankle and hindfoot surgery was associated with a low wearing compliance and did not influence ankle swelling, function, pain, and the quality of life compared to the control group. Furthermore, the clinical results of patients with high compliance were not better compared to the results of patients with low or noncompliance wearing behavior.

scholarly journals Antioxidant Lifestyle, Co-Morbidities and Quality of Life Empowerment Concerning Liver Fibrosis

Antioxidants ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 1125
Author(s):  
Diego Martinez-Urbistondo ◽  
Rafael Suarez del Villar ◽  
Josepmaria Argemí ◽  
Lidia Daimiel ◽  
Omar Ramos-López ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Demographic Data ◽  
Univariate Analysis ◽  
Multivariable Analysis ◽  
Alcoholic Fatty Liver ◽  
Co Morbidity ◽  
Sf 36

The assessment of liver fibrosis has gained importance since the progression of non-alcoholic fatty liver disease (NAFLD). Indeed, the description of the association between undetected liver fibrosis and lifestyle in terms of antioxidant habits, comorbidity and quality of life (QoL) domains may help in the characterization of subjects with NAFLD. A cross-sectional evaluation of (n = 116) consecutive patients from an Internal Medicine ambulatory evaluation was performed. Demographic data, lifestyle, co-morbidity, QoL (according to the SF-36 index) and analytical values to calculate the oxidative related Fibrosis-4 (FIB-4) index were recorded. The association between FIB-4 and co-morbidity, antioxidant habits in QoL was assessed in univariate analysis (p < 0.05) and confirmed in multivariable analysis for 4 of the 8 SF-36 categories: Physical QoL, Physical role, Social QoL and General QoL, as well as in the Physical summary of SF-36 (p < 0.05). Finally, interactions were assessed between co-morbidity, FIB-4 and antioxidant habits showed in the prediction of mean SF-36 (p < 0.01). Liver fibrosis assessed by the oxidative surrogate index FIB-4 is associated with the interaction between antioxidant lifestyle, co-morbidity and physical, social and general aspects of QoL in apparent liver disease-free individuals, generating a proof of concept for health empowerment and personalized medicine.

Sign in / Sign up

Export Citation Format

Share Document